Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Raj K. Maturi, MD
Annual Meeting Talks
2021
Characteristics and Outcomes of nAMD Patients Managed in US Routine Clinical Practice: Analysis of the IRIS Registry Database
Anita Barikian, MD
Annual Meeting Talks
2022
Clinical Feasibility of Ultra-rapid, Non-pharmacologic Anesthesia for Intravitreal Injection in Patients Receiving Anti-VEGF
Cagri G Besirli, MD, PhD, FASRS
Updates from the Field
2018

Category: AMD-Neovascular

See more